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On the orders o f magnitude of epigenic dynamics
and monoclonal antibody production
J. M. Savinell, G. M. Lee and B. O. Paisson, Ann Arbor

Abstract. The hybridoma cell's maximum capacity for monoclonal

antibody (MAb) production is estimated to be 2300-8000 MAb
molecules/cell/s, using measured rates of transcription and translation, and the limitations imposed by the size of the polymerase
molecule and the ribosome. Nearly al! the production rates reported
in the literature fall into or below this range of production rates.
Data from batch cultures of hybridomas demonstrate a constant
specific rate of MAb production until the time integral of the viable
cell concentration reaches about 108 cells ·h/cm3. At this point,
some essential nutrients from the standard media are depleted, causing MAb production to decline.
1 Introduction
Rapidly growing markets for monoclonal antibodies (MAbs)
have brought about the large-scale cultivation of hybridomas and the development of optimal processing schemes.
The preliminary analysis needed for process design requires
us to seek order of magnitudes of key rates, capacities, and
other necessary data for orientation and identification of
factors that need quantitative analysis. Herein we attempt to
establish how basic biochemical and cellular determinants
set the order of magnitude of the rate of monoclonal antibody production. Our order of magnitude estimate is consistent with experimental observations.
2 Dynamics of antibody synthesis
Antibody synthesis in hybridoma cells proceeds in a sequence of several well-known steps, shown in Fig. 1. These
steps are transcription, processing of the heteronuclear RNA
(hnRNA), translation, assembly of polypeptides and their
glycosylation, and secretion of the antibody. Antibody accounts for a large fraction of protein synthesized in Ab-producing cells. For instance, in rapidly growing MOPC 21 and
MPC 11 myeloma cells, a single gene for each of the heavy
(H) and light (L) chains may provide enough mRNA that
leads to about 20-30% of the protein synthesized [1].
We will now estimate the theoretical maximum rate of
antibody synthesis, which is the steady state flux through

the Ab production system. 1 These order of magnitude calculations will give an upper bound on the specific productivity
of hybridoma cells, and are based on the cell's capacity for
transcription and translation. 2 The maximum capacity for
the other stages of Ab synthesis, such as glycosylation and
secretion, are more difficult to evaluate at present. However,
these steps would only serve to reduce our estimate of the
maximum Ab synthesis rate, ifthey would prove to be capacity limiting. As will be shown below, the estimate based on
the processes of transcription and translation agrees with
experimental data.
A dynamic mass balance on the cytoplasmic Ab mRNA
concentration is:
d[mRNA]
---=
dt

v
- c· D · E - k · [ m R N A ] - µ - [ m R N A ] ,
Sc

(1)

where [mRN A] is the number of mRNA per cell in the cytoplasm, D is the gene dosage, which for hybridomas is equal
to one gene per cell; E is the fraction of nuclear mRNA which
reaches the cytoplasm; vc is the velocity of the polymerase II
molecule in nucleotides/s/gene; sc is the spacing of nucleotides between polymerase molecules on the DNA, with
units nucleotides/polymerase; k is the degradative rate constant related to the half life of mRNA, in s - 1; µ is the growth
rate, in s- 1 .
Assuming that in balanced growth, the amount of mRNA
per cell is in a quasi-steady state, we obtain
[mRNAJ ss

=

v ·D·E 1
C
·--.
sC· k
µ
1+k

(2)

Such an estimate should not be confused with the characteristic
response times associated with the individual steps in the process.
For example, the response time, defined as the approximate
length of time for the process to occur, is 20-150 min for the
glycosylation/secretion step [2, 3], and 40 min for nuclear processing [4]. Although these may be the steps in the Ab synthesis
pathway with the slowest response times, they do not necessarily
limit the cell's capacity for Ab synthesis.
2 Similar calculations have been used to estima te the rate of zymogen synthesis in cocoonase zymogen cells [5].
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Fig. 1. Pathway of antibody synthesis

The various parameters appearing in this expression may
be estimated from the available literature. Reported values
for vc are 83 nucleotides/s for HeLa ribosomal RNA [6], 67
in poliovirus [7], and 45 in E. coli [8]. The reported values for
se are 75 nucleotides/polymerase in E. coli [9], and 79-92 in
Triturus viridescens [10). Based on the physical size of the
polymerase II molecule, the minimum spacing is about 38
nucleotides [10], although it is unlikely that this spacing can
be physically achieved. Approximately 70-90% of the hnR N A produced in the nucleus is transported to the cytoplasm [11], so E falls in the range of 0.7-0.9. The average
half-life of Ab mRN A has been measured to be 12 h [12],
corresponding to a k value of 1.61 · 10- 5 s - 1. Minimum
doubling times for hybridomas are on the order of 12-14 h
and µ is therefore less than or equal to k. Consequently, the
factor 1 - falls in the range 0.5-1.0. For doubling times of

1+t':k

14-20 h, this factor takes values in the range of 0.54-0.63.
Using the parameter values most appropriate for myeloma
cells, we obtain the estimated range for [mRNAJ ss :

can exhibit significant turnover - L chains are reported to be
produced in excess of H chains [3]. The rate of H chain
synthesis thus forms a suitable upper bound on the MAb
excretion rate.
The range of the maximum Ab synthesis rate can then be
calculated using Eq. (3) with the parameter values appropriate for the myeloma cell, and the mRN A concentrations that
were calculated previously:
VAb

= -1 . - - - -20
- -to- -25
- -nucleotides/s
--

2 90 to 100 nucleotides/ribosome

·(23,000 to 58,000 mRN A/cell)

= 2300 to

8000 Ab/cell/s.

Therefore, based on the physical constraints enumerated
above (the observed polymerase and ribosome packing density, and transcription and translation velocities), the theoretical maximum output of antibody from a myeloma cell is
on the order of 2300-8000 Ab molecules/cell/s. If the maximum estimated value of 122,000 mRNA/cell is used, the upper limit for the A b production rate becomes 17,000 Ab
molecules/cell/s.

hnRNA]
(83 nucleotides/s) ·(0.7 to 0.9)
·(0.5to1.0)
.
(80 nucleotldes/polymerase) (1.61 · 10- 5 s - 1)
= 23,000 to 58,000 H or L mRN A molecules/cell.

The reported estimates of 54,000 LmRNA/cell [11], and
40,000 LmRNA and 30,000 H mRNA [13] fall within this
range. The upper limit for the [mRNA] ss can be extended to
122,000 mRNA molecules/cell if the minimum polymerase
spacing of 38 nucleotides/polymerase is used.
The equation for translation of Ab mRN A, assuming that
translation is a first order process [14], is:
VAb

1 vs

= - · - · [mRNA] ss ·
2

SS

(3)

We assume that the ribosome concentration is not limiting
and, therefore, the translation rate is independent of ribosome concentration. Reported values for the ribosome velocity, vs , are 20 nucleotides/s in myeloma [1], 25 in reticulocytes [15], and 48-60 in Salmonella typhinurium [16]. The
number of nucleotides between ribosomes, S8 , is reported to
be 90-100 in myeloma [1] and reticulocytes [15], and 88-99
in somatotropes and mammotropes [17]. The factor of 0.5
occurs because two H and two L polypeptide chains are
needed for the assembly of one complete Ab molecule. To
estimate the maximum Ab production rate, we have neglected the turnover of either the H or L chains. The H
chains are believed to be relatively stable, whîle the L chains

3 Discussion
The reported values of MAb production range from 17 to
8000 Ab/cell/s for various hybridoma cell lines (Table 1),
with most values falling in the range of 500-3000. Our estimate of the maximum rate seems, therefore, reasonable.
Fig. 2 shows the normalized MAb concentration plotted
against the time integral of the viable cell concentration, for
several sets ofbatch data reported in the literature. The slope
of this curve, which gives the specific productivity, is nearly
linear up to the point around 10 8 cells ·h/cm 3 for all the data
used. At this point, one or more critical components seem to
be depleted from the standard media, causing the MAb production to decline [18]. It has been shown that when the
essential amino acids were added to the media at this point,
the cells continued to synthesize antibody at the same rate
[18]. Figure 2 indicates that the specific productivity of MAb
is nearly constant at the individual cell line's characteristic
rate, as long as the necessary nutrients are available. All
these data sets corne from experiments with 5-10% serum
in the media. Data from our laboratory show that the
specific MAb production rate is serum independent [19],
except under long term adaptation to very low serum levels
(unpublished results).
The high MAb-producing hybridoma cell lines, shown in
Table 1, secrete MAb at rates that are close to our estimated
capacity of the epigenic system. If nutritional conditions are
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not limiting, improvements in the specific MAb production
rate will not be achieved through improved processing technology but rather through modification of cellular components. At present it is uncertain how successfully we can
manipulate the cell's protein synthesis machinery.
Our results, therefore, support the view that economically
successful large-scale cultivation of hybridomas is likely to
depend primarily on the selection of: 1) a high producer, and
2) a processing scheme that supports high cell densities .
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Fig. 2. Antibody concentration plotted against the time integral of
the cell concentration, for cells grown in batch cultures. The antibody concentrations are normalized against the maximum antibody
concentration for that cell line. Sources of the data are: 111[20];
e , 0 [21]; A [22]; • [23]; Il [24]; .t. [25]

Table 1. Reported antibody production rates
Ab production rate
molecules/cell/s

Reference

1200-2700
580
530-4650
480
17-33
6000
470-790
8000
830
355-470
2230
970
210

[26]
[27]
[28]
[29]
[30]
[31]
[32]
[33]
[20]
[18]
[22]
[25]
[24]

Semi-continuous
mouse VII H-8, IgG2a
human HF10B4, IgM

490-750
62

[28]
[34]

Continuo us
mouse VII H-8, IgG2a
mouse 65/26, IgG2b/x
mouse N-146, IgG
mouse N-226, IgG
mouse N-527, IgG
mouse S-6, IgG
mouse S-84, IgM
rat R33-18-12
rat R33-24-12
rat R33-60
rat IM/41
rat C2-23
mouse 143, IgG2a
mouse NB1, IgM

460-1400
80-2550
5800
615
7640
1210
380
2460
110
675
3400
2330
330-670
60

[28]
[29]
[33]
[33]
[33]
[33]
[33]
[33]
[33]
[33]
[33]
[33]
[35]
[36]

Cell line
Batch
mouse
mouse
mouse
mouse
mouse
mouse
mouse
mouse
mouse
mouse
mouse
mouse
mouse

HB8178, IgG
VII H-8, IgG2a
VII H-8, IgG2a
65/26, IgG2b/x
455, IgG2a
B103, IgG
MRC Ox-19, IgG
N-527 IgG
J4C2 IgG1
HB 32 IgG2aK
9.2.27 IgG2a
IgG
S3H5/ybA2, IgG2bA
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